121 related articles for article (PubMed ID: 24269688)
21. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.
Kukreja R; Chang TW; Cai S; Lindo P; Riding S; Zhou Y; Ravichandran E; Singh BR
Toxicon; 2009 May; 53(6):616-24. PubMed ID: 19673075
[TBL] [Abstract][Full Text] [Related]
22. Egg yolk antibodies for detection and neutralization of Clostridium botulinum type A neurotoxin.
Trott DL; Yang M; Gonzalez J; Larson AE; Tepp WH; Johnson EA; Cook ME
J Food Prot; 2009 May; 72(5):1005-11. PubMed ID: 19517727
[TBL] [Abstract][Full Text] [Related]
23. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.
Bryant AM; Cai S; Singh BR
Toxicon; 2013 Sep; 72():126-32. PubMed ID: 23811077
[TBL] [Abstract][Full Text] [Related]
24. Development and characterization of six monoclonal antibodies to hemagglutinin-70 of Clostridium botulinum and their application in a sandwich ELISA.
Scotcher MC; Cheng LW; Ching K; McGarvey J; Hnasko R; Stanker L
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):6-15. PubMed ID: 23600499
[TBL] [Abstract][Full Text] [Related]
25. Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies.
Sharma SK; Ferreira JL; Eblen BS; Whiting RC
Appl Environ Microbiol; 2006 Feb; 72(2):1231-8. PubMed ID: 16461671
[TBL] [Abstract][Full Text] [Related]
26. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
[TBL] [Abstract][Full Text] [Related]
27. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity Associated with Botulinum Toxin Treatment.
Bellows S; Jankovic J
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31454941
[TBL] [Abstract][Full Text] [Related]
29. Immunological properties of Hn-33 purified from type A Clostridium botulinum.
Sharma SK; Singh BR
J Nat Toxins; 2000 Nov; 9(4):357-62. PubMed ID: 11126514
[TBL] [Abstract][Full Text] [Related]
30. Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments.
Joshi SG; Elias M; Singh A; Al-Saleem FH; Ancharski D; Nasser Z; Takahashi T; Simpson LL
Neuroscience; 2011 Apr; 179():208-22. PubMed ID: 21277940
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of botulinum toxin immunogenicity.
Benecke R
BioDrugs; 2012 Apr; 26(2):e1-9. PubMed ID: 22385408
[TBL] [Abstract][Full Text] [Related]
32. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).
Torii Y; Takahashi M; Ishida S; Goto Y; Nakahira S; Harakawa T; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2010; 55(2-3):662-5. PubMed ID: 19781565
[TBL] [Abstract][Full Text] [Related]
33. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.
Göschel H; Wohlfarth K; Frevert J; Dengler R; Bigalke H
Exp Neurol; 1997 Sep; 147(1):96-102. PubMed ID: 9294406
[TBL] [Abstract][Full Text] [Related]
34. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.
Wu HC; Yeh CT; Huang YL; Tarn LJ; Lung CC
Appl Environ Microbiol; 2001 Jul; 67(7):3201-7. PubMed ID: 11425742
[TBL] [Abstract][Full Text] [Related]
35. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
36. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.
Mazuet C; Dano J; Popoff MR; Créminon C; Volland H
PLoS One; 2010 Aug; 5(8):e12416. PubMed ID: 20865035
[TBL] [Abstract][Full Text] [Related]
37. Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies.
Liu Z; Song C; Li Y; Liu F; Zhang K; Sun Y; Li H; Wei Y; Xu Z; Zhang C; Yang A; Xu Z; Yang K; Jin B
Anal Chim Acta; 2012 Jul; 735():23-30. PubMed ID: 22713913
[TBL] [Abstract][Full Text] [Related]
38. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
Marks JD
Mov Disord; 2004 Mar; 19 Suppl 8():S101-8. PubMed ID: 15027061
[TBL] [Abstract][Full Text] [Related]
39. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.
Webb RP; Smith TJ; Wright P; Brown J; Smith LA
Vaccine; 2009 Jul; 27(33):4490-7. PubMed ID: 19450643
[TBL] [Abstract][Full Text] [Related]
40. Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.
Kato K; Akaike N; Kohda T; Torii Y; Goto Y; Harakawa T; Ginnaga A; Kaji R; Kozaki S
Toxicon; 2013 Nov; 74():109-15. PubMed ID: 23954512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
